| Index | S&P 500 | P/E | 23.50 | EPS (ttm) | 4.06 | Insider Own | 0.15% | Shs Outstand | 1.28B | Perf Week | 0.70% |
| Market Cap | 122.05B | Forward P/E | 14.92 | EPS next Y | 6.39 | Insider Trans | -3.57% | Shs Float | 1.28B | Perf Month | 7.80% |
| Enterprise Value | 141.43B | PEG | 2.99 | EPS next Q | 1.34 | Inst Own | 57.68% | Short Float | 3.13% | Perf Quarter | 13.29% |
| Income | 5.23B | P/S | 3.25 | EPS this Y | 8.32% | Inst Trans | 0.00% | Short Ratio | 4.54 | Perf Half Y | 14.51% |
| Sales | 37.54B | P/B | 2.40 | EPS next Y | 6.99% | ROA | 5.61% | Short Interest | 39.97M | Perf YTD | -0.68% |
| Book/sh | 39.75 | P/C | 13.84 | EPS next 5Y | 7.86% | ROE | 10.60% | 52W High | 106.33 -10.27% | Perf Year | -0.51% |
| Cash/sh | 6.89 | P/FCF | 19.90 | EPS past 3/5Y | 9.77% 7.00% | ROIC | 6.44% | 52W Low | 73.31 30.15% | Perf 3Y | 31.24% |
| Dividend Est. | 2.88 (3.02%) | EV/EBITDA | 13.90 | Sales past 3/5Y | 5.21% 3.84% | Gross Margin | 66.69% | Volatility | 2.39% 2.53% | Perf 5Y | -25.32% |
| Dividend TTM | 2.86 (3.00%) | EV/Sales | 3.77 | EPS Y/Y TTM | 12.47% | Oper. Margin | 18.08% | ATR (14) | 2.40 | Perf 10Y | 14.52% |
| Dividend Ex-Date | Sep 25, 2026 | Quick Ratio | 2.09 | Sales Y/Y TTM | 11.94% | Profit Margin | 13.93% | RSI (14) | 59.78 | Recom | 2.37 |
| Dividend Gr. 3/5Y | 1.96% 4.42% | Current Ratio | 2.07 | EPS Q/Q | -10.49% | SMA20 | 5.18% | Beta | 0.59 | Target Price | 97.73 |
| Payout | 69.79% | Debt/Eq | 0.56 | Sales Q/Q | 13.73% | SMA50 | 4.43% | Rel Volume | 0.36 | Prev Close | 96.59 |
| Employees | 95,000 | LT Debt/Eq | 0.52 | Earnings | Nov 17 | SMA200 | 8.15% | Avg Volume | 16.65M | Price | 95.41 |
| IPO Date | May 02, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.43% 2.20% | Net Debt/EBITDA | 2.60 | Volume | 6,007,236 | Change | -1.22% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | BTIG | Buy | $100 → $99 |
| Oct-06-26 | Initiated | Barclays | Equal Weight | $118 → $95 |
| Sep-03-26 | Reiterated | Deutsche Bank | Buy | $78 → $92 |
| Sep-03-26 | Reiterated | UBS | Buy | $100 → $110 |
| Sep-02-26 | Reiterated | Mizuho Securities | Outperform | $100 → $115 |
| Sep-02-26 | Reiterated | Stifel Nicolaus | Hold | $80 → $95 |
| Sep-02-26 | Reiterated | Truist Securities | Hold | $86 → $99 |
| Sep-02-26 | Reiterated | Wells Fargo | Overweight | $114 → $104 |
| Sep-01-26 | Reiterated | BTIG | Buy | $91 → $100 |
| Aug-27-26 | Reiterated | Needham | Buy | $101 → $114 |
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 4/24/2026 | FY 2025 4/25/2025 | FY 2024 4/26/2024 | FY 2023 4/28/2023 | FY 2022 4/29/2022 | FY 2021 4/30/2021 | FY 2020 4/30/2020 | FY 2019 4/26/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 37,542 | 36,364 | 33,537 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12,505 | 12,721 | 11,632 | — | — | — | — | — | — | |
| Gross Profit | 25,037 | 23,643 | 21,905 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 12,176 | 11,784 | 10,849 | — | — | — | — | — | — | |
| Research and Development | 2,918 | 2,873 | 2,732 | — | — | — | — | — | — | |
| Other Operating Expense | 3,160 | 2,522 | 2,369 | — | — | — | — | — | — | |
| Operating Income | 6,786 | 6,467 | 5,955 | — | — | — | — | — | — | |
| Interest Expense | 725 | 715 | 729 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 542 | 384 | 402 | — | — | — | — | — | — | |
| Net Income Before Taxes | 6,603 | 6,136 | 5,628 | — | — | — | — | — | — | |
| Income Taxes | 1,333 | 1,299 | 936 | — | — | — | — | — | — | |
| Consolidated Net Income | 5,230 | 4,800 | 4,662 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 5,270 | 4,837 | 4,691 | — | — | — | — | — | — | |
| Net Income | 5,230 | 4,800 | 4,662 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.09 | 3.75 | 3.63 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.09 | 3.75 | 3.63 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.06 | 3.73 | 3.61 | — | — | — | — | — | — | |
| EBITDA | 10,177 | 9,809 | 9,218 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.50 | 22.34 | 23.31 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.25 | 2.94 | 3.23 | — | — | — | — | — | — | |
| Gross Margin | 66.69 | 65.02 | 65.32 | — | — | — | — | — | — | |
| Operating Margin | 18.08 | 17.78 | 17.76 | — | — | — | — | — | — | |
| Net Margin | 13.93 | 13.20 | 13.90 | — | — | — | — | — | — | |
| Shares Outstanding | 1,280 | 1,282 | 1,286 | — | — | — | — | — | — | |
| Market Capitalization | 122,125 | 106,816 | 108,230 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Marinaro Michael | EVP, Pres MedSurg and Americas | Oct 15 '26 | Sale | 96.00 | 10,420 | 1,000,320 | 105,916 | Oct 16 |
| Martha Geoffrey | Chairman and CEO | Oct 15 '26 | Sale | 95.00 | 50,000 | 4,750,000 | 277,866 | Oct 16 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | Sep 16 '26 | Sale | 93.65 | 1,483 | 138,883 | 42,186 | Sep 17 |
| Walter Matthew R. | SVP, Chief HR Officer | Jul 08 '26 | Sale | 83.15 | 3,102 | 257,931 | 35,694 | Jul 09 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | Jun 08 '26 | Sale | 80.44 | 4,189 | 336,966 | 37,227 | Jun 09 |
| Walter Matthew R. | SVP, Chief HR Officer | May 26 '26 | Option Exercise | 0.00 | 17,598 | 0 | 41,529 | May 28 |
| Wall Brett A. | EVP & Pres Neuroscience | May 26 '26 | Option Exercise | 0.00 | 51,121 | 0 | 82,183 | May 28 |
| Martha Geoffrey | Chairman and CEO | May 26 '26 | Option Exercise | 0.00 | 180,424 | 0 | 343,099 | May 28 |
| Marinaro Michael | EVP, Pres MedSurg and Americas | May 26 '26 | Option Exercise | 0.00 | 36,087 | 0 | 70,593 | May 28 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | May 26 '26 | Option Exercise | 0.00 | 29,712 | 0 | 48,233 | May 28 |
| Blomquist Denise L. | Chief Accounting Officer | May 26 '26 | Option Exercise | 0.00 | 3,333 | 0 | 14,974 | May 28 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | Feb 19 '26 | Option Exercise | 90.90 | 50,876 | 4,624,511 | 85,292 | Feb 26 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | Feb 19 '26 | Sale | 97.71 | 52,524 | 5,132,217 | 32,768 | Feb 26 |
| Smith Gregory L | EVP Global Ops & Supply Chain | Nov 19 '25 | Sale | 101.95 | 30,000 | 3,058,452 | 46,016 | Nov 21 |
| KIIL HARRY SKIP | EVP & President Cardiovascular | Sep 03 '25 | Sale | 91.58 | 8,605 | 788,048 | 35,615 | Sep 05 |